Jeroen N. Hiltermann

Groningen, GR 9713GZ, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

The Association and Predictive Value of Nutritional and Inflammatory Biomarkers in Advanced Non-Small Cell Lung Cancer Response to Immune Checkpoint Inhibitors.

The Association and Predictive Value of Nutritional and Inflammatory Biomarkers in Advanced Non-Small Cell Lung Cancer Response to Immune Checkpoint Inhibitors.

Journal: Cancers

Published: May 27, 2026

Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab.

Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 10, 2026

Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.

Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 29, 2026

Flow Enabled Target Capture Halbach-based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients.

Flow Enabled Target Capture Halbach-based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients.

Journal: Molecular oncology

Published: January 19, 2026

Multidisciplinary tumor boards (MTBs) and survival Outcomes: Adherence to MTB recommendations in patients with lung cancer treated at two European cancer centers (AdThera-2).

Multidisciplinary tumor boards (MTBs) and survival Outcomes: Adherence to MTB recommendations in patients with lung cancer treated at two European cancer centers (AdThera-2).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 05, 2025

Association of CT-assessed sarcopenia and the development of immune-related adverse events and overall survival: a multistate survival analysis.

Association of CT-assessed sarcopenia and the development of immune-related adverse events and overall survival: a multistate survival analysis.

Journal: Translational lung cancer research

Published: October 03, 2025

Cell-Free DNA Based Next-Generation Sequencing Does Not Differentiate Between Oligoprogression and Systemic Progression in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors-An Explorative Study.

Cell-Free DNA Based Next-Generation Sequencing Does Not Differentiate Between Oligoprogression and Systemic Progression in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors-An Explorative Study.

Journal: International journal of molecular sciences

Published: July 01, 2025

Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum.

Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: A clinical case series of a diverse spectrum.

Journal: JAAD case reports

Published: June 20, 2025

Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib.

Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib.

Journal: Targeted oncology

Published: May 07, 2025

Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatment.

Quality of life, neurocognitive functioning, psychological issues, sexuality and comorbidity more than 2 years after commencing immune checkpoint inhibitor treatment.

Journal: Journal for immunotherapy of cancer

Published: March 07, 2025

Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model.

Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: February 21, 2025

Changes in global quality of life after treatment with immune checkpoint inhibitors in patients receiving different treatment regimens for advanced stage lung cancer in the Netherlands: a 2015-2021 cohort study.

Changes in global quality of life after treatment with immune checkpoint inhibitors in patients receiving different treatment regimens for advanced stage lung cancer in the Netherlands: a 2015-2021 cohort study.

Journal: BMJ open

Published: February 20, 2025

Showing 1-12 of 77

Last Updated: 09/26/2026